Skip to main content
. Author manuscript; available in PMC: 2016 May 16.
Published in final edited form as: Am J Ophthalmol. 2007 Dec 11;145(2):257–266. doi: 10.1016/j.ajo.2007.09.025

FIGURE 1.

FIGURE 1

Patient 2, a 50-year-old Caucasian woman with choroidal neovascularization (CNV) attributable to birdshot chorioretinopathy (BCR). Studies obtained at baseline and two, four, and 24 weeks after the first infusion are shown including best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters read at 4 meters and Snellen equivalent, frames from early, mid, and late phases of fluorescein angiograms (FA), and horizontal and vertical cross-sections of optical coherence tomography (OCT) scans labeled T-N (temporal-nasal) and I-S (inferior-superior), respectively. At the primary endpoint of 24 weeks after the first infusion, the patient showed improved BCVA, reduced CNV lesion size, and reduction in leakage and edema, but not complete resolution.